Abiopharma

🔍 Schmalzle Ronald R (Executive)

Company: NORWOOD FINANCIAL CORP (NWFL)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 40 shares of Common Stock at $34.02 per share (Direct)
  Date: 2026-08-10 | Code: A | equity_swap_involved: false | shares_owned_after: 8,918.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: H | nature_of_ownership: IRA | shares_owned_after: 27,768.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: H | nature_of_ownership: Restricted Stock | shares_owned_after: 550.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: H | nature_of_ownership: Restricted Stock | shares_owned_after: 825.00 | Footnotes: F3

Footnotes:

• F1: Director Retainer Shares issued under the 2024 Equity Incentive Plan.
• F2: Award vests in three equal installments beginning December 15, 2025 and annually thereafter during such periods of continued service as an Employee, Outside Director or Director Emeritus, as applicable.
• F3: Award vests in three equal installments beginning on December 15, 2026 and annually thereafter during such periods of continued service as an Employee, Outside Director or Director Emeritus, as applicable.